Base de dados : HANSEN
Pesquisa : ANTIINFECCIOSOS [Descritor de assunto]
Referências encontradas : 29 [refinar]
Mostrando: 1 .. 20   no formato [Detalhado]

página 1 de 2 ir para página        

  1 / 29 HANSEN  
              next record last record
seleciona
para imprimir
Id:23973
Autor:Scollard, D. M; Adams, L. B; Gillis, T. P; Krahenbuhl, J. L; Truman, R. W; Williams, D. L
Título:The continuing challenges of leprosy
..-
Fonte:s.l; s.n; 2006. 44 p. ilus, tab.
Resumo:Leprosy is best understood as two conjoined diseases. The first is a chronic mycobacterial infection that elicits an extraordinary range of cellular immune responses in humans. The second is a peripheral neuropathy that is initiated by the infection and the accompanying immunological events. The infection is curable but not preventable, and leprosy remains a major global health problem, especially in the developing world, publicity to the contrary notwithstanding. Mycobacterium leprae remains noncultivable, and for over a century leprosy has presented major challenges in the fields of microbiology, pathology, immunology, and genetics; it continues to do so today. This review focuses on recent advances in our understanding of M. leprae and the host response to it, especially concerning molecular identification of M. leprae, knowledge of its genome, transcriptome, and proteome, its mechanisms of microbial resistance, and recognition of strains by variable-number tandem repeat analysis. Advances in experimental models include studies in gene knockout mice and the development of molecular techniques to explore the armadillo model. In clinical studies, notable progress has been made concerning the immunology and immunopathology of leprosy, the genetics of human resistance, mechanisms of nerve injury, and chemotherapy. In nearly all of these areas, however, leprosy remains poorly understood compared to other major bacterial diseases. (AU).
Descritores:Antiinfecciosos/TU
Proteínas de Bactérias/ME
Vacinas Bacterianas
Modelos Animais de Doenças
Suscetibilidade à Doença/IM
Resistência Bacteriana a Drogas
Genes Bacterianos/GE
Predisposição Genética para Doença
Genoma Bacteriano
Imunidade Celular
Imunidade Natural/GE
Hansenostáticos/PD/TU
Hanseníase/*/DI/MI/TH
Mycobacterium leprae/*/CH/DE/IP/PH
Nervos Periféricos/MI
Doenças do Sistema Nervoso Periférico/MI/PA
Reação em Cadeia da Polimerase
Research Support, N.I.H., Extramural
Células de Schwann/IM/MI
Limites:HUMANO
ANIMAL
CAMUNDONGOS
SUPPORT, NON-U.S. GOV'T
Localização:BR191.1; 09365/S


  2 / 29 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:22733
Autor:Grimald, J; Vallat, J. M
Título:Manifestations neurologiques de la lepre
Neurological manifestations of leprosy-
Fonte:s.l; s.n; 2003. 19 p. .
Resumo:Leprosy, also known as Hansen's disease, is a chronic, infectious disease caused by Mycobacterium leprae. Bacilli localize preferentially in the skin and peripheral nerves and have a propensity to cause nerve damage. The resulting disability has caused great suffering for victims in many countries. Despite recent advances in the immunopathogenesis, epidemiology and prognostic factors of leprosy nerve damage, many aspects of the disease have remained enigmatic. The spectrum of clinical and pathological manifestations of the disease ranges from lepromatous to tuberculoid, depending on the host's T-cell-mediated immune response. Diagnosis is based on three criteria: characteristic skin lesions in association with thickened nerves, demonstration of acid fast bacilli in slit skin smears, and histopathology of skin biopsies. Nerve biopsy is necessary to establish the diagnosis of pure "neural leprosy". In developed countries, the diagnosis is suspected when a patient who has stayed in an endemic area suffers from a peripheral neuropathy of unknown etiology. To facilitate determination of the appropriate antibiotic regimen, patients are classified as either paucibacillary or multibacillary. Some patients may have multibacillary leprosy in nerves and paucibacillary leprosy in skin, which emphasizes the usefulness of nerve biopsy. The course of the disease is often complicated by immune mediated "reactions", which can rapidly lead to further nerve damage, namely reversal reaction and erythema nodosum leprosy. However, nerves are often functionally impaired before developing obvious symptoms such as skin reactions or nevralgia (silent neuropathy). Early recognition and prompt treatment with corticosteroids of leprous reactions and "silent neuropathies" is very important to prevent disability with all its attendant problems. Research progress from clinical trials may improve current methods of prevention and treatment of nerve damage in leprosy.(AU).
Descritores:Antiinfecciosos/TU
Biópsia
Diagnóstico Diferencial
Hanseníase/DT/*PA/VI
Mycobacterium leprae/IP
Nervos Periféricos/*PA/VI
Pele/VI
Limites:Humano
Localização:BR191.1; 00254/s


  3 / 29 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:20767
Autor:Salem, Isam Ismail; Steffan, Gerhard; Düzgünes, Nejat
Título:Efficacy of clofazimine - modified cyclodextrin against Mycobacterium avium complex in human macrophages
..-
Fonte:s.l; s.n; 2003. 10 p. graf.
Resumo:Clofazimine, a water insoluble substituted iminophenazine derivative with anti-mycobacterial and anti-inflammatory activity, is recommended by the WHO for the treatment of leprosy. It is also active against disseminated Mycobacterium avium complex (MAC) disease in HIV-infected patients. Recently, we achieved a 4000-fold increase of clofazimine water solubility using a novel modified clofazimine-cyclodextrin complex synthesized and patented by our group [Wasserlösliche, Iminiophenazinderivate enthaltende pharmazeutische Zusammensetzungen, deren Herstellung und Verwendung, German Patent, DE19814814C2]. In this paper we examine the activity of this complex against MAC in human macrophages, and evaluate its cytotoxicity. MAC-infected macrophages were treated for 24h with free or complexed clofazimine. The in vitro minimum inhibitory concentrations of both free and complexed clofazimine were 0.1 microg/ml. Free and complexed clofazimine inhibited the growth of MAC inside macrophages to a similar extent, while modified cyclodextrin alone had no observable effects on MAC or macrophages. Complexed clofazimine was not toxic to cells at concentrations effective against MAC. The TD(50) of the modified cyclodextrin in THP-1 cell line was 297 microg/ml. (AU).
Descritores:ANTIINFECCIOSOS/quim
ANTIINFECCIOSOS/farmacol
ANTIINFECCIOSOS/tox
CELULAS CULTIVADAS
CLOFAZIMINA/quim
CLOFAZIMINA/farmacol
CLOFAZIMINA/tox
MACROFAGOS/ef drogas
TESTES DE SENSIBILIDADE MICROBIANA
COMPLEXO MYCOBACTERIUM AVIUM/ef drogas
ESTEROIS/quim
ACIDO SUCCINICO
Limites:ESTUDO COMPARATIVO
HUMANO
ANIMAL
CAMUNDONGOS
Meio Eletrônico: - .
Localização:BR191.1; 09082/s


  4 / 29 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18954
Autor:Salem, Isam Ismail; Steffan, Gerhard; Düzgünes, Nejat
Título:Efficacy of clofazimine - modified cyclodextrin against Mycobacterium avium complex in human macrophages
..-
Fonte:s.l; s.n; 2003. 10 p. graf.
Resumo:Clofazimine, a water insoluble substituted iminophenazine derivative with anti-mycobacterial and anti-inflammatory activity, is recommended by the WHO for the treatment of leprosy. It is also active against disseminated Mycobacterium avium complex (MAC) disease in HIV-infected patients. Recently, we achieved a 4000-fold increase of clofazimine water solubility using a novel modified clofazimine-cyclodextrin complex synthesized and patented by our group [Wasserlösliche, Iminiophenazinderivate enthaltende pharmazeutische Zusammensetzungen, deren Herstellung und Verwendung, German Patent, DE19814814C2]. In this paper we examine the activity of this complex against MAC in human macrophages, and evaluate its cytotoxicity. MAC-infected macrophages were treated for 24h with free or complexed clofazimine. The in vitro minimum inhibitory concentrations of both free and complexed clofazimine were 0.1 microg/ml. Free and complexed clofazimine inhibited the growth of MAC inside macrophages to a similar extent, while modified cyclodextrin alone had no observable effects on MAC or macrophages. Complexed clofazimine was not toxic to cells at concentrations effective against MAC. The TD(50) of the modified cyclodextrin in THP-1 cell line was 297 microg/ml. (AU).
Descritores:ANTIINFECCIOSOS/quim
ANTIINFECCIOSOS/farmacol
ANTIINFECCIOSOS/tox
CLOFAZIMINA/quim
CLOFAZIMINA/farmacol
CLOFAZIMINA/tox
CELULAS CULTIVADAS
MACROFAGOS/ef drogas
MACROFAGOS/microbiol
TESTES DE SENSIBILIDADE MICROBIANA
COMPLEXO MYCOBACTERIUM AVIUM/ef drogas
ESTEROIS/quim
ACIDO SUCCINICO/quim
Limites:ESTUDO COMPARATIVO
HUMANO
ANIMAL
CAMUNDONGOS
Meio Eletrônico: - .
Localização:BR191.1; 09082/s


  5 / 29 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18001
Autor:Tarabini-Castellani, Giovanni
Título:El Bactrim en el mal perforante plantar hanseniano
..-
Fonte:s.l; s.n; July-Dec. 1971. 22 p. .
Resumo:As a first step, two groups of 34 leprosy patients with perforating ulcers were included in this...(AU).
Descritores:ESTUDOS DE AVALIACAO
ANTIINFECCIOSOS/uso terap
ANTAGONISTAS DO ACIDO FOLICO/uso terap
DOENCAS DO PE/quimioter
HANSENIASE/quimioter
TRIMETOPRIM/uso terap
ULCERA/quimioter
PENICILINAS/uso terap
 PIRIMIDINAS/uso terap
 SULFAMETOXAZOL/uso terap
 TETRACICLINA/uso terap
Limites:ESTUDO COMPARATIVO
ADOLESCENTE
Meio Eletrônico: - .
Localização:BR191.1; 01220/s


  6 / 29 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:16331
Autor:Maeda, Shinji; Matsuoka, Masanori; Nakata, Noboru; Kai, Masanori; Maeda, Yumi; Hashimoto, Ken; Kimura, Hiroaki; Kobayashi, Kazuo; Kashiwabara, Yoshiko
Título:Multidrug resistant mycobacterium leprae from patients with leprosy
..-
Fonte:s.l; s.n; Dec. 2001. 5 p. tab, graf.
Descritores:AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA
AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA
ANTIBIOTICOS ANTITUBERCULOSE
ANTIBIOTICOS ANTITUBERCULOSE
SEQUENCIA DE BASES
PRIMERS DO DNA
DNA BACTERIANO
DNA BACTERIANO
RESISTENCIA MICROBIANA A DROGAS
RESISTENCIA A MULTIPLAS DROGAS
GENES BACTERIANOS
GENES BACTERIANOS
LEPROSTATICOS
LEPROSTATICOS
HANSENIASE
HANSENIASE
CAMUNDONGOS
DADOS DE SEQUENCIA MOLECULAR
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
OFLOXACINA
OFLOXACINA
RIFAMPINA
RIFAMPINA
REACAO EM CADEIA POR POLIMERASE VIA TRANSCRIPTASE REVERSA
Limites:ANIMAL
Localização:BR191.1; 08640/s


  7 / 29 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:16213
Autor:Ochoa, Maria Teresa; Stenger, Steffer; Sieling, Peter A; Thoma-Uszynski, Sybille; Sabet, Shereen; Cho, Sungae; Krensky, Alan M; Rollinghoff, Martin; Sarno, Euzenir Nunes; Burdick, Anne E; Rea, Thomas H; Modlin, Robert L
Título:T-cell release of granulysin contributes to host defense in leprosy
..-
Fonte:s.l; s.n; feb. 2001. 6 p. ilus, graf.
Descritores:ANTIINFECCIOSOS
ANTIGENOS CD3
ANTIGENOS DE DIFERENCIAÇAO DE LINFOCITOS T
ANTIGENOS DE DIFERENCIAÇAO DE LINFOCITOS T
LINFOCITOS T CD4-POSITIVOS
HANSENIASE LEPROMATOSA
HANSENIASE LEPROMATOSA
HANSENIASE TUBERCULOIDE
HANSENIASE TUBERCULOIDE
Células Cultivadas
Localização:BR191.1; 08698/s


  8 / 29 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:16013
Autor:Cohen, Jack B
Título:Cutaneous involvement of dermatomyositis can respond to dapsone therapy
..-
Fonte:s.l; s.n; 2002. 3 p. .
Descritores:DERMATOMIOSITE
DERMATOMIOSITE
ANTIINFECCIOSOS
DAPSONA
DIAGNOSTICO DIFERENCIAL
HIDROXICLOROQUINA
IMUNOSSUPRESSORES
PREDNISONA
QUINACRINA
Localização:BR191.1; 08596/s


  9 / 29 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15783
Autor:Sehgal, Virendra N; Kumar, Sunil; Jain, Sanjiv; Bhattacharya, Samit N
Título:Relapse (reactivation) in borderline tuberculoid (BT) leprosy
..-
Fonte:s.l; s.n; 1998. 2 p. ilus.
Descritores:HANSENIASE DIMORFA
HANSENIASE DIMORFA
HANSENIASE TUBERCULOIDE
HANSENIASE TUBERCULOIDE
LEPROSTATICOS
AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA
ANTIBIOTICOS TETRACICLINICOS
DAPSONA
GRANULOMA
HISTIOCITOS
LINFOCITOS
MINOCICLINA
RECIDIVA
RIFAMPINA
Limites:ADULTO
HUMANO
MASCULINO
Localização:BR191.1; 07324/s


  10 / 29 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15741
Autor:Ochoa, Maria-Teresa; Stenger, Steffen; Sieling, Peter A; Thoma-Uszynski, Sybille; Sabet, Shereen; Cho, Sungae; Krensky, Alan M; Rollinghoff, Martin; Sarno, Euzenir Nunes; Burdick, Anne E; Rea, Thomas H; Modlin, Robert L
Título:T-cell release of granulysin contributes to host defense in leprosy
..-
Fonte:s.l; s.n; 2001. 6 p. ilus, graf.
Descritores:HANSENIASE LEPROMATOSA
HANSENIASE LEPROMATOSA
HANSENIASE TUBERCULOIDE
HANSENIASE TUBERCULOIDE
ANTIINFECCIOSOS
ANTIGENOS CD3
ANTIGENOS DE DIFERENCIAÇAO DE LINFOCITOS T
ANTIGENOS DE DIFERENCIAÇAO DE LINFOCITOS T
LINFOCITOS T CD4-POSITIVOS
Localização:BR191.1; 08477/s


  11 / 29 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15739
Autor:Paniker, Uma; Levine, Norman
Título:Dapsone and sulfapyridine
..-
Fonte:s.l; s.n; 2001. 8 p. ilus, tab.
Descritores:HANSENIASE
DERMATOPATIAS
ANTIINFECCIOSOS
ANTIINFECCIOSOS
ANTIINFECCIOSOS
ANTIINFECCIOSOS
ANTIINFLAMATORIOS NAO ESTEROIDES
ANTIINFLAMATORIOS NAO ESTEROIDES
ANTIINFLAMATORIOS NAO ESTEROIDES
ANTIINFLAMATORIOS NAO ESTEROIDES
DAPSONA
DAPSONA
DAPSONA
DAPSONA
AGENTES DERMATOLOGICOS
AGENTES DERMATOLOGICOS
AGENTES DERMATOLOGICOS
AGENTES DERMATOLOGICOS
SULFAPIRIDINA
SULFAPIRIDINA
SULFAPIRIDINA
SULFAPIRIDINA
Localização:BR191.1; 08475/s


  12 / 29 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15693
Autor:Cohen, Jack B
Título:Cutaneous involvement of dermatomyositis can respond to dapsone therapy
..-
Fonte:s.l; s.n; 2002. 3 p. .
Descritores:DERMATOMIOSITE
DERMATOMIOSITE
ANTIINFECCIOSOS
DAPSONA
DIAGNOSTICO DIFERENCIAL
HIDROXICLOROQUINA
IMUNOSSUPRESSORES
PREDNISONA
QUINACRINA
Localização:BR191.1; 08504/s


  13 / 29 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15472
Autor:Consigny, Sophie; Bentoucha, Abdelhalim; Bonnafous, Pascale; Grosset, Jacques; Ji, Baohong
Título:Bactericidal activities of HMR 3647, monofloxacin, and rifapentine against mycobacterium leprae in mice
..-
Fonte:s.l; s.n; 2000. 3 p. tab.
Descritores:AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA
AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA
ANTIBIOTICOS MACROLIDIOS
ANTIBIOTICOS MACROLIDIOS

LEPROSTATICOS
LEPROSTATICOS
HANSENIASE
HANSENIASE
CAMUNDONGOS
TESTES DE SENSIBILIDADE MICROBIANA
MYCOBACTERIUM LEPRAE
RIFAMPINA
RIFAMPINA
RIFAMPINA
Limites:ESTUDO COMPARATIVO
ANIMAL
Localização:BR191.1; 08327/s


  14 / 29 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15331
Autor:John, Deepa; Daniel, Ebenezer
Título:Infectious keratitis in leprosy
..-
Fonte:s.l; s.n; 1999. 4 p. tab.
Descritores:ANTIINFECCIOSOS
CIPROFLOXACINA
ULCERA DA CORNEA
ULCERA DA CORNEA
KETOCONAZOL
HANSENIASE LEPROMATOSA
HANSENIASE TUBERCULOIDE
FATORES DE RISCO
ACUIDADE VISUAL
Localização:BR191.1; 07252/s


  15 / 29 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15329
Autor:Villahermosa, Laarni G; Walsh, Douglas S; Fajardo Junior, Tranquilino T; Abalos, Rodolfo M; dela Cruz, Eduardo C; Veerasubramanian, Priya; Walsh, Gerald P
Título:Resolution of lepromatous leprosy after a short course of amoxicillin / clavulanic acid, followed by ofloxacin and clofazimine
..-
Fonte:s.l; s.n; 1999. 3 p. ilus.
Descritores:AMOXICILINA
ANTIINFECCIOSOS
ACIDOS CLAVULANICOS
CLOFAZIMINA
QUIMIOTERAPIA COMBINADA
HANSENIASE LEPROMATOSA
HANSENIASE LEPROMATOSA
HANSENIASE LEPROMATOSA
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
OFLOXACINA
PELE
PELE
RESULTADO DE TRATAMENTO
Localização:BR191.1; 07250/s


  16 / 29 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15042
Autor:Zoprbas, P; Kontochristopoulos, G; Detsi, I; Apostolakis, E; Kouris, N; Katsambas, A
Título:Borderline tuberculoid leprosy coexisting with systemic lupus erythematosus
..-
Fonte:s.l; s.n; may 1999. 2 p. .
Descritores:AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA
ANTIINFLAMATORIOS ESTEROIDES
CIPROFLOXACINA
ULCERA DO PÉ
ULCERA DO PÉ
HANSENIASE DIMORFA
HANSENIASE DIMORFA
HANSENIASE DIMORFA
LUPUS ERITEMATOSO SISTEMICO
LUPUS ERITEMATOSO SISTEMICO
LUPUS ERITEMATOSO SISTEMICO
PREDNISOLONA
Limites:RELATO DE CASO
Localização:BR191.1; 07489/s


  17 / 29 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:14250
Autor:Bermudez, Luiz E
Título:Use of liposome preparation to treat mycobacterial infections
..-
Fonte:s.l; s.n; 1994. 6 p. .
Descritores:INFECÇOES OPORTUNISTAS RELACIONADAS COM A AIDS
INFECÇOES OPORTUNISTAS RELACIONADAS COM A AIDS
ANTIINFECCIOSOS
ANTITUBERCULOSOS
PORTADORES DE DROGAS
HANSENIASE
LIPOSSOMOS
MICOBACTERIOSE
MICOBACTERIOSE
INFECÇAO POR MYCOBACTERIUM AVIUM-INTRACELLULARE
TUBERCULOSE
TUBERCULOSE RESISTENTE A MULTIPLAS DROGAS
Localização:BR191.1; 06961/s


  18 / 29 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:14211
Autor:Chan, Gertrude P; Garcia-Ignacio, Bernadette Y; Chavez, Virginia E; Livelo, Jocelyn B; Jimenez, Claribel L; Parrilla, Manuela Luisa R; Franzblau, Scott G
Título:Clinical trial of sparfloxacin for lepromatous leprosy
..-
Fonte:s.l; s.n; 1994. 5 p. tab.
Descritores:AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA
ANTIGENOS DE BACTÉRIAS

GLICOLIPIDIOS
HANSENIASE LEPROMATOSA
HANSENIASE LEPROMATOSA
CAMUNDONGOS
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
OXIRREDUÇAO
ACIDOS PALMITICOS
QUINOLONAS
ESPIROMETRIA
Localização:BR191.1; 06913/s


  19 / 29 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:14166
Autor:Bermudez, Luiz E
Título:Use of liposome preparation to treat mycobacterial infections
..-
Fonte:s.l; s.n; 1994. 6 p. .
Descritores:HANSENIASE
INFECÇOES OPORTUNISTAS RELACIONADAS COM A AIDS
INFECÇOES OPORTUNISTAS RELACIONADAS COM A AIDS
ANTIINFECCIOSOS
ANTITUBERCULOSOS
PORTADORES DE DROGAS
LIPOSSOMOS
MICOBACTERIOSE
INFECÇAO POR MYCOBACTERIUM AVIUM-INTRACELLULARE
TUBERCULOSE
TUBERCULOSE RESISTENTE A MULTIPLAS DROGAS
Localização:BR191.1; 07080/s


  20 / 29 HANSEN  
              first record previous record
seleciona
para imprimir
Id:14139
Autor:Cambau, Emmanuelle; Perani, Evelyne; Guillemin, Isabelle; Jamet, Pierre; Ji, Baohong
Título:Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae
..-
Fonte:s.l; s.n; 1997. 2 p. tab.
Descritores:AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA
DAPSONA
RESISTENCIA A MULTIPLAS DROGAS
QUIMIOTERAPIA COMBINADA
LEPROSTATICOS
HANSENIASE LEPROMATOSA
HANSENIASE LEPROMATOSA
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
OFLOXACINA
RIFAMPINA
Limites:RELATO DE CASO
Localização:BR191.1; 07114/s



página 1 de 2 ir para página        
   


Refinar a pesquisa
  Base de dados : HANSEN Formulário avançado   
Pesquisar por : Formulário livre   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6.1 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information